Acceptance of Group Application Under Public Law 95-202 and Department of Defense Directive (DODD) 1000.20, 58773 [2022-20980]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 187 / Wednesday, September 28, 2022 / Notices
immunotherapy to be advanced out of
turn for examination. To date, over 880
petitions requesting participation in the
pilot program have been filed, and over
650 patents have been granted under the
program. In view of the continued
interest in the Cancer Immunotherapy
Pilot Program, as well as the White
House’s reignition of the National
Cancer Moonshot initiative, the USPTO
is extending the program, with all
parameters remaining the same, until
January 31, 2023. The USPTO will also
continue to evaluate whether to expand
the scope of the pilot program and to
what extent during this extension
period.
DATES: Pilot duration: The Cancer
Immunotherapy Pilot Program will
continue to run until January 31, 2023.
Therefore, petitions to make special
under the Cancer Immunotherapy Pilot
Program must be filed on or before
January 31, 2023.
FOR FURTHER INFORMATION CONTACT: For
questions regarding this pilot program
in general, please contact Susy TsangFoster, Senior Legal Advisor, Office of
Patent Legal Administration, Office of
the Deputy Commissioner for Patent
Examination Policy, at 571–272–7711 or
susy.tsang-foster@uspto.gov. For
questions related to a particular
petition, please contact Gary B. Nickol,
Supervisory Patent Examiner, at 571–
272–0835 or gary.nickol@uspto.gov; or
Brandon J. Fetterolf, Supervisory Patent
Examiner, at 571–272–2919 or
brandon.fetterolf@uspto.gov, both of
Technology Center 1600.
SUPPLEMENTARY INFORMATION: On June
29, 2016, the USPTO published a notice
for the implementation of the Cancer
Immunotherapy Pilot Program. See
Cancer Immunotherapy Pilot Program,
81 FR 42328 (Cancer Immunotherapy
Notice). The pilot program was designed
to support the global fight against
cancer. The Cancer Immunotherapy
Notice indicated that an applicant could
have an application advanced out of
turn (accorded special status) for
examination without meeting all the
current requirements of the accelerated
examination program set forth in item
VIII of section 708.02(a) of the Manual
of Patent Examining Procedure (9th ed.,
rev. 10.2019, June 2020), if the
application contained at least one claim
to a method of treating a cancer using
immunotherapy and the applicant met
other requirements specified in the
Cancer Immunotherapy Notice.
The Cancer Immunotherapy Notice
established that the pilot program
would run for 12 months, beginning on
June 29, 2016. Over the course of the
pilot program, the USPTO has extended
VerDate Sep<11>2014
18:06 Sep 27, 2022
Jkt 256001
it four times through notices published
in the Federal Register. The most recent
notice extended the program until
September 30, 2022 and requested
public comments on whether to expand
the scope of pilot program and whether
to extend it. See Extension of the Cancer
Immunotherapy Pilot Program and
Request for Comments, 87 FR 38714
(June 29, 2022) (Extension Notice). The
Office received one written submission
containing three comments from a law
firm in response to the request for
public comments in the Extension
Notice. The Office appreciates the
thoughtful comments. The submission
is posted at https://
www.regulations.gov/document/PTO-P2022-0019-0001/comment. The USPTO
is continuing to evaluate whether to
expand the program and to what extent.
Various stakeholders from around the
world—including independent
inventors, universities, research
institutions, hospitals, medical centers,
government agencies, and large and
small companies—have filed petitions
to participate in the pilot program. To
date, over 880 petitions requesting
participation have been filed, and over
650 patents have been granted under the
pilot program. In view of the continued
interest in the pilot program, the USPTO
is hereby extending it through January
31, 2023. The extension will enable the
program to continue without lapse as
the USPTO continues its ongoing
evaluation of whether to expand the
program and to what extent. The
requirements of the pilot program will
not be modified at this time.
Katherine K. Vidal,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. 2022–20988 Filed 9–27–22; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF DEFENSE
Department of the Air Force
Acceptance of Group Application
Under Public Law 95–202 and
Department of Defense Directive
(DODD) 1000.20
Department of the Air Force,
DoD Civilian/Military Service Review
Board.
ACTION: Notice.
AGENCY:
Under the provisions of
Section 401, Public Law 95–202 and
DoD Directive 100.20, the Department of
Defense Civilian/Military Service
Review Board has accepted an
application on behalf of a group known
SUMMARY:
PO 00000
Frm 00010
Fmt 4703
Sfmt 4703
58773
as ‘‘Former Members of the Free Iraq
Forces and Free Iraq Civil Affairs
Program Who Served Under Direct
Command of U.S. Army and U.S.
Marine Corps Units During Operation
Iraqi Freedom Across the Iraqi Freedom
Theater of Operations During the Period
2002 Through 2018.’’ Persons with
information or documentation pertinent
to the determination of whether service
of this group should be considered
active military service to the Armed
Forces of the United States are
encouraged to submit such information
or documentation within 60 days to the
DoD Civilian/Military Service Review
Board (DoD C/MSRB), 1500 West
Perimeter Road, Suite 3700, Joint Base
Andrews, MD 20762.
FOR FURTHER INFORMATION CONTACT: Mr.
John K. Vallario, President, DoD C/
MSRB, at 240–612–5380,
john.vallario.1@us.af.mil. Copies of
documents or other materials submitted
cannot be returned.
Adriane Paris,
Air Force Federal Register Liaison Officer.
[FR Doc. 2022–20980 Filed 9–27–22; 8:45 am]
BILLING CODE 5001–10–P
DEPARTMENT OF DEFENSE
Department of the Navy
Certificate of Alternate Compliance for
USS AUGUSTA (LCS 34)
Department of the Navy (DoN),
Department of Defense (DoD).
ACTION: Notice of issuance of certificate
of alternate compliance.
AGENCY:
The U.S. Navy hereby
announces that a Certificate of Alternate
Compliance has been issued for USS
AUGUSTA (LCS 34). Due to the special
construction and purpose of this vessel,
the Admiralty Counsel of the Navy has
determined it is a vessel of the Navy
which, due to its special construction
and purpose, cannot comply fully with
the navigation lights provisions of the
International Regulations for Preventing
Collisions at Sea, 1972 (72 COLREGS)
without interfering with its special
function as a naval ship. The intended
effect of this notice is to warn mariners
in waters where 72 COLREGS apply.
DATES: This Certificate of Alternate
Compliance is effective September 28,
2022 and is applicable beginning
September 21, 2022.
FOR FURTHER INFORMATION CONTACT:
Lieutenant Commander Andrea Liou,
JAGC, U.S. Navy, Admiralty Attorney,
Office of the Judge Advocate General,
Admiralty and Claims Division (Code
SUMMARY:
E:\FR\FM\28SEN1.SGM
28SEN1
]]>Agencies
[Federal Register Volume 87, Number 187 (Wednesday, September 28, 2022)]
[Notices]
[Page 58773]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20980]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Air Force
Acceptance of Group Application Under Public Law 95-202 and
Department of Defense Directive (DODD) 1000.20
AGENCY: Department of the Air Force, DoD Civilian/Military Service
Review Board.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Under the provisions of Section 401, Public Law 95-202 and DoD
Directive 100.20, the Department of Defense Civilian/Military Service
Review Board has accepted an application on behalf of a group known as
``Former Members of the Free Iraq Forces and Free Iraq Civil Affairs
Program Who Served Under Direct Command of U.S. Army and U.S. Marine
Corps Units During Operation Iraqi Freedom Across the Iraqi Freedom
Theater of Operations During the Period 2002 Through 2018.'' Persons
with information or documentation pertinent to the determination of
whether service of this group should be considered active military
service to the Armed Forces of the United States are encouraged to
submit such information or documentation within 60 days to the DoD
Civilian/Military Service Review Board (DoD C/MSRB), 1500 West
Perimeter Road, Suite 3700, Joint Base Andrews, MD 20762.
FOR FURTHER INFORMATION CONTACT: Mr. John K. Vallario, President, DoD
C/MSRB, at 240-612-5380, [email protected]. Copies of documents
or other materials submitted cannot be returned.
Adriane Paris,
Air Force Federal Register Liaison Officer.
[FR Doc. 2022-20980 Filed 9-27-22; 8:45 am]
BILLING CODE 5001-10-P
